Quantitative EEG Analysis in Angelman Syndrome: Candidate Method for Assessing Therapeutics

Area of Science:

• Neuroscience
• Biomarkers
• Pediatrics

Background:

• Angelman syndrome (AS) is a rare neurodevelopmental disorder.
• Characteristic EEG patterns are observed in AS, but quantitative analysis is needed.
• Objective measures are crucial for evaluating therapeutic efficacy in AS.

Purpose of the Study:

• To utilize quantitative EEG (qEEG) spectral power analysis as a biomarker for Angelman syndrome.
• To assess qEEG's utility in evaluating therapeutic efficacy for AS.
• To analyze EEG changes in AS patients during minocycline treatment.

Main Methods:

• Collected and analyzed baseline EEG data from children with AS and neurotypical controls.
• Assessed spectral power and epileptiform events in AS patients during a minocycline clinical trial.
• Compared pre-treatment, on-treatment, and post-washout EEG data.

Main Results:

• Confirmed elevated total and delta power in AS patients compared to controls.
• Observed increased delta power in AS patients at baseline and during minocycline treatment.
• Found significantly reduced EEG spectral power and epileptiform activity after minocycline washout in AS patients.

Conclusions:

• Quantitative EEG analysis is a viable method for evaluating Angelman syndrome.
• qEEG shows potential as a quantitative measure for assessing therapeutic efficacy in AS.
• Normalizing EEG power may serve as a key metric for screening AS therapeutics.